PI
AMRI

Putnam Investments’s Albany Molecular Research Inc AMRI Stock Holding History

Putnam Investments’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-131,887
Closed -$1.85M – 1408
2017
Q1 		$1.85M Sell
131,887
-13,989
-10% -$229K ﹤0.01% 879
2016
Q4 		$2.74M Sell
145,876
-1,884
-1% -$32K 0.01% 763
2016
Q3 		$2.44M Sell
147,760
-130,999
-47% -$1.94M 0.01% 793
2016
Q2 		$3.75M Buy
+278,759
New +$4.07M 0.01% 761

Other funds holding AMRI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Putnam Investments's AMRI Position: Q2 2017 in Review

Putnam Investments sold out of Albany Molecular Research Inc (AMRI) in Q2 2017, closing a stake of 131,887 shares — an estimated $1.85M sold.

Putnam Investments first reported a position in AMRI in Q2 2016 and held it in 4 quarters. The position peaked at $3.75M in Q2 2016. 136 funds tracked by Wall St. Rank hold AMRI as of Q2 2017.

  • Putnam Investments reported no remaining Albany Molecular Research Inc position as of Q2 2017 after selling out during the quarter.
  • Putnam Investments sold 131,887 Albany Molecular Research Inc shares in Q2 2017, an estimated $1.85M.
  • Putnam Investments first reported a position in Albany Molecular Research Inc in Q2 2016 and held it in 4 quarters.
  • Putnam Investments's Albany Molecular Research Inc position peaked at $3.75M in Q2 2016.
  • 136 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2017.

Based on Putnam Investments's 13F filing for Q2 2017, filed 14 Aug 2017.